MGTX
$7.65
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.
Recent News
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +38.89% and +53.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +77.78% and +280.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -28.71% and -3.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +78.53% and +28.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -60.45% and +0.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?